$ABBV has reached an agreement with the Trump administration to address upcoming U.S. drug pricing reforms. The deal is aimed at providing more clarity and flexibility around how new pricing rules for Medicare and Medicaid will be implemented, helping AbbVie reduce regulatory uncertainty while avoiding harsher mandatory controls. For AbbVie, the agreement could protect long-term revenue visibility as pricing pressure on big pharma continues to rise. For policymakers, it signals a more cooperative approach with drugmakers rather than aggressive enforcement. The move may also set a precedent for how other pharmaceutical companies negotiate future pricing frameworks. Will this encourage more pharma companies to cut deals with regulators, or does it risk slowing real progress on lowering drug costs for patients?